In 2017, the FDA approved FXR agonist and, currently, numerous FXR agonists are under clinical trials for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) (Le et al., 2012). Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.